Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation.

The RET proto-oncogene encodes a transmembrane receptor with tyrosine kinase activity. Germline mutations in RET are responsible for a number of inherited diseases. These include the dominantly inherited cancer syndromes multiple endocrine neoplasia types 2A and 2B (MEN 2A and MEN 2B) and familial medullary thyroid carcinoma (FMTC), as well as some cases of familial Hirschsprung disease (HSCR1). RET mutations in HSCR1 have been shown to cause a loss of RET function, while the cancer syndromes result in RET oncogenic activation. Occasionally MEN 2A or FMTC occurs in association with HSCR1, albeit with low penetrance. An initial report linked HSCR1 in MEN 2A solely to the C618R and C620R RET mutations. In this study we have analyzed 44 families with MEN 2A. HSCR1 co-segregated with MEN 2A in seven (16%) of the 44 families. The predisposing RET mutation in all seven families had been previously reported in MEN 2A or FMTC and occurred in exon 10 at codons 609, 618 or 620, resulting in C609Y, C618S, C620R or C620W substitution. MEN 2A families with RET exon 10 Cys mutations had a substantially greater risk of developing HSCR1 than those with the more common RET exon 11 Cys634 or exon 14 c804 mutations (P = 0.0005). These findings suggest that expression of HSCR1 in MEN 2A may be peculiar to RET exon 10 Cys mutations . However, HSCR1 in MEN 2A is not exclusive to C618R or C620R RET mutations and can occur with other exon 10 Cys amino acid substitutions. The strong correlation between disease phenotype and position of the MEN 2A RET mutation suggests that oncogenic activation of RET alone is insufficient to account for co-expression of the diseases.

[1]  J. BeatoNunez,et al.  [Hirschsprung's disease]. , 1951, Revista cubana de pediatria.

[2]  M. Verdy,et al.  Hirschsprung's disease in a family with multiple endocrine neoplasia type 2. , 1982, Journal of pediatric gastroenterology and nutrition.

[3]  L. Lerman,et al.  Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. , 1987, Methods in enzymology.

[4]  R. A. Decker,et al.  Dinucleotide repeat polymorphisms at the D10S183 and D10S245 loci. , 1992, Human molecular genetics.

[5]  R. A. Decker,et al.  Dinucleotide repeat polymorphism at the D10S469 locus. , 1993, Human molecular genetics.

[6]  A. Beaudet,et al.  Retroviral mediated expression of CD18 in normal and deficient human bone marrow progenitor cells. , 1993, Human molecular genetics.

[7]  T. Lairmore,et al.  A 1.5-megabase yeast artificial chromosome contig from human chromosome 10q11.2 connecting three genetic loci (RET, D10S94, and D10S102) closely linked to the MEN2A locus. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Goodfellow,et al.  Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. , 1993, Human molecular genetics.

[9]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[10]  B. Ponder,et al.  Mutations of the RET proto-oncogene in Hirschsprung's disease , 1994, Nature.

[11]  Masashi Yanagisawa,et al.  A missense mutation of the endothelin-B receptor gene in multigenic hirschsprung's disease , 1994, Cell.

[12]  B. Ponder,et al.  Erratum: Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours (Human Molecular Genetics (1994) 3 (237-241)) , 1994 .

[13]  D. Clayton,et al.  Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC , 1994, Nature Genetics.

[14]  P. Goodfellow,et al.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Hofstra,et al.  A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma , 1994, Nature.

[16]  L. Mulligan,et al.  Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. , 1994, Human molecular genetics.

[17]  B. Pasini,et al.  Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease , 1994, Nature.

[18]  A. Munnich,et al.  Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. , 1995, Human molecular genetics.

[19]  X. Matías-Guiu,et al.  Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas , 1995, Cancer.

[20]  B. Ponder,et al.  A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC. , 1995, Oncogene.

[21]  al. et,et al.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.

[22]  R. A. Decker,et al.  Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. , 1995, Surgery.

[23]  A. Chakravarti,et al.  Mutation analysis of the RET receptor tyrosine kinase in Hirschsprung disease. , 1995, Human molecular genetics.

[24]  M. Schlumberger,et al.  RET mutations in exons 13 and 14 of FMTC patients. , 1995, Oncogene.

[25]  N. Asai,et al.  Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations , 1995, Molecular and cellular biology.

[26]  A. Munnich,et al.  Mutation of the endothelin-3 gene in the Waardenburg-Hirschsprung disease (Shah-Waardenburg syndrome) , 1996, Nature Genetics.

[27]  A. Munnich,et al.  C618R mutation in exon 10 of the RET proto-oncogene in a kindred with multiple endocrine neoplasia type 2A and Hirschsprung's disease. , 1996, The Journal of clinical endocrinology and metabolism.

[28]  N. Asai,et al.  Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. , 1996, Human molecular genetics.

[29]  Carel Meijers,et al.  A homozygous mutation in the endothelin-3 gene associated with a combined Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg syndrome) , 1996, Nature Genetics.

[30]  C Eng,et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.

[31]  R. A. Decker,et al.  Detection of RET mutations in multiple endocrine neoplasia type 2a and familial medullary thyroid carcinoma by denaturing gradient gel electrophoresis , 1996, Human mutation.

[32]  C. Sklar,et al.  Clinical presentations and RET protooncogene mutations in seven multiple endocrine neoplasia type 2 kindreds , 1996, Cancer.

[33]  Vittorio,et al.  Molecular heterogeneity of RET loss of function in Hirschsprung's disease. , 1996, The EMBO journal.

[34]  A. Biton,et al.  Cys 618 Arg mutation in the RET proto‐oncogene associated with familial medullary thyroid carcinoma and maternally transmitted Hirschsprung's disease suggesting a role for imprinting , 1997, Human mutation.

[35]  R. A. Decker,et al.  Update on the profile of multiple endocrine neoplasia type 2a RET mutations , 1997 .

[36]  G. Sobue,et al.  Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype. , 1997, Cancer research.

[37]  R. Hutchison.  Hirschsprung's Disease. , 1913, Proceedings of the Royal Society of Medicine.